Skip to main content

View full-text article in PMC

. 2018 Oct 2;35(11):225. doi: 10.1007/s11095-018-2501-7

Table IV.

Frequency of Spontaneous Bowel Movement Responders and Gastrointestinal Disorders

Spontaneous bowel movement responder in the PK/efficacy population^a
Study No.	Dose (mg)		Non_Responder		Responder
1107 V9221 (Phase 2b)	0		37 (60.7)		24 (39.3)
	0.1		4 (44.4)		5 (55.6)
	0.2		3 (33.3)		6 (66.7)
	0.4		4 (40.0)		6 (60.0)
1314 V9231 and 1315 V9232 (Phase 3)	0		361 (65.9)		187 (34.1)
	0.2		208 (46.7)		237 (53.3)
Gastrointestinal disorders in the PK/safety population^b
Study No.	Dose (mg)	Not_Reported	Mild	Moderate	Severe
1107 V9221 (Phase 2b)	0	53 (86.9)	6 (9.8)	2 (3.3)	0 (0.0)
	0.1	7 (77.8)	1 (11.1)	1 (11.1)	0 (0.0)
	0.2	5 (55.6)	1 (11.1)	3 (33.3)	0 (0.0)
	0.4	7 (70.0)	2 (20.0)	1 (10.0)	0 (0.0)
1314 V9231 and 1315 V9232 (Phase 3)	0	473 (86.3)	47 (8.6)	21 (3.8)	7 (1.3)
	0.2	351 (78.9)	52 (11.7)	34 (7.6)	8 (1.8)

^aCount (Percent)

^bCount (Row percent)